Premium
Prognostic role of FEV 1 for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation
Author(s) -
Ahn Jee Hwan,
Jo KyungWook,
Song Jin Woo,
Shim Tae Sun,
Lee Sei Won,
Lee Jae Seung,
Kim DaeYoung,
Lee JeHwan,
Lee JungHee,
Choi Yunsuk,
Lee KyooHyung
Publication year - 2015
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.12638
Subject(s) - bronchiolitis obliterans , medicine , hematopoietic stem cell transplantation , transplantation , survival rate , retrospective cohort study , lung transplantation , surgery , survival analysis , gastroenterology
Background Bronchiolitis obliterans syndrome ( BOS ) can occur after hematopoietic stem cell transplantation ( HSCT ) and is associated with significant mortality. We investigated the role of forced expiratory volume in one s ( FEV 1 ) as a prognostic marker in BOS after HSCT . Methods Among all patients who underwent HSCT between December 1993 and November 2013 at a tertiary center in S outh K orea, 1187 patients were enrolled. Patient medical records were retrospectively analyzed to evaluate the prognostic factors associated with survival in these cases. Results During a median follow‐up period of 30.7 months after HSCT , 82 patients (6.9%) were diagnosed with BOS . The mean FEV 1 of the BOS patients was 34.7% of predicted, and the mean FEV 1 of 31 of these patients (37.8%) was <30% of predicted. The estimated overall survival rate for BOS patients excluding three patients who received lung transplantation was 74% at three yr from BOS diagnosis. Multivariate analysis showed that diagnosis of BOS within six months and FEV 1 < 30% of predicted at the time of BOS diagnosis were associated with shorter survival. Conclusions An FEV 1 < 30% of predicted at the time of diagnosis is significantly associated with an increased risk of death in patients with BOS after HSCT .